The importance of IGF signaling in the modulation of response of melanoma, ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, colorectal cancer, and several other cancers to chemotherapeutic agents has been validated. The gene discussed is IGF1; the disease is breast carcinoma.